Four studies which use innovative technologies such as gene editing and next-generation sequencing were presented to the American Epilepsy Society’s (AES) 69th 14 April 2020 Meeting. Researchers from the University of California used gene-editing technology in zebrafish to reveal how gene mutations affect development, while researchers from the Eip4K Consortium uncovered de novo mutations in around 300 genes. The possibility of using FDA-approved drugs which reduce faulty cell signalling between nerve cells was studied by researchers from Emory University and the fourth study, by researchers from British Columbia Children’s Hospital and the University of British Columbia, examined whole-exome sequencing.
Four studies which use innovative technologies such as gene editing and next-generation sequencing were presented to the American Epilepsy Society’s (AES) 69th Annual Meeting. Researchers from the University of California used gene-editing technology in zebrafish to reveal how gene mutations affect development, while researchers from the Eip4K Consortium uncovered de novo mutations in around 300 genes. The possibility of using FDA-approved drugs which reduce faulty cell signalling between nerve cells was studied by researchers from Emory University and the fourth study, by researchers from British Columbia Children’s Hospital and the University of British Columbia, examined whole-exome sequencing.